Special Care Service for Lung Cancer

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen byBrian Henick, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Columbia University

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.

Eligibility Criteria

This trial is for adults over 18 with confirmed non-small cell lung cancer (NSCLC) who are receiving immunotherapy and identify as part of an ethnic minority or underserved group. They must understand the study and agree to participate. Those in other clinical trials or with conditions that may hinder participation cannot join.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document

I am 18 years old or older.

I have been diagnosed with non-small cell lung cancer.

See 2 more

Exclusion Criteria

Presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study

Patients enrolled in other interventional clinical trials at the time of screening will be excluded.

Treatment Details

Interventions

Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation (Behavioural Intervention)

Trial OverviewThe Apricity C.A.R.E. Program is being tested to see if it can improve treatment results for NSCLC patients from racial/ethnic minorities on immunotherapy, aiming to reduce their need for frequent healthcare visits.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention ArmExperimental Treatment1 Intervention

Participants are provided with ApricityRx digital solution with pulse oximeters and 24/7 C.A.R.E. (Cancer Adverse event Rapid Evaluation) to monitor and capture ePRO, identify onset or progression of symptoms verified by nurse triage, trigger intervention by the study team.

Group II: Control ArmActive Control1 Intervention

Clinicians will monitor NSCLC patients on ICIs for irAEs as a standard of care using routine practices.